Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
Seminars in Cancer Biology|May 22, 2018
Emerging biomarkers for immune checkpoint inhibition in lung cancerGeorge Cyriac, Leena Gandhi
JAMA Oncology|June 17, 2016
Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A ReviewAdrian G Sacher, Leena Gandhi
Journal of the National Comprehensive Cancer Network : JNCCN|July 4, 2006
Paraneoplastic syndromes associated with small cell lung cancerLeena Gandhi, Bruce E Johnson
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 2, 2012
Crizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new targetLeena Gandhi, Pasi A Jänne
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 27, 2014
Management and future directions in non-small cell lung cancer with known activating mutationsDavid E Gerber, Leena Gandhi, Daniel B Costa
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 15, 2019
2017-2018 Scientific Advances in Thoracic Oncology: Small Cell Lung CancerStefan Zimmerman, Arundhati Das, Shuhang Wang, et al.
Cancer|February 8, 2007
A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancerLeena Gandhi, Matthew W Harding, Marcus Neubauer, et al.
British Journal of Cancer|November 15, 2018
A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumoursAlison M Schram, Leena Gandhi, Monica M Mita, et al.
European Journal of Radiology|February 13, 2017
Co-clinical quantitative tumor volume imaging in ALK-rearranged NSCLC treated with crizotinibMizuki Nishino, Adrian G Sacher, Leena Gandhi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 15, 2014
CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancerRebecca S Heist, Xiaofei Wang, Lydia Hodgson, et al.
Pageof 7